IP Library Granted Patent US 9,132,184
Granted Patent B2
US 9,132,184 · App. 12/513,935 · Granted Sep 15, 2015

Stabilization of vaccines by lyophilization

Inventors: Daniel C. Vellom (Sudbury, MA); James E. Woiszwillo (Watertown, MA); Paul DeGeorge (Norwood, MA); Peter Ciarametaro (Gloucester, MA)
Assignee: Sanofi Pasteur Biologics, LLC
A61K39/12C07K14/005A61K9/19A61K2039/5254C12N2770/24122C12N2770/24134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,184
App. No.
12/513,935
Granted
Sep 15, 2015
Kind
B2
Abstract

This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.

Claims (20)

1. A freeze-dried composition comprising a live, attenuated flavivirus , one or more stabilizers, one or more buffer components, lactose, and amorphous mannitol.

2. The composition of claim 1 , wherein the stabilizer is human serum albumin (HSA).

3. The composition of claim 2 , wherein the human serum albumin is non-recombinant human serum albumin (HSA) or recombinant human serum albumin (rHA).

4. The composition of claim 1 , comprising histidine and/or potassium glutamate as a buffer component.

5. The composition of claim 2 , wherein said human serum albumin is present in said composition at a concentration of about 0.05-2.0% prior to freeze-drying.

6. The composition of claim 1 , wherein said mannitol and/or lactose is present in said composition at a concentration of about 2-10% prior to freeze-drying.

7. The composition of claim 4 , wherein said histidine is present in said composition at a concentration of about 1-20 mM prior to freeze-drying.

8. The composition of claim 4 , wherein said potassium glutamate is present in said composition at a concentration of about 20-80 mM prior to freeze-drying.

9. The composition of claim 1 , wherein said live, attenuated flavivirus is a chimeric flavivirus that comprises a first flavivirus in which one or more structural proteins have been replaced with corresponding structural proteins of a second, different flavivirus.

10. The composition of claim 9 , wherein the membrane and envelope proteins of said first flavivirus have been replaced with membrane and envelope proteins of said second, different flavivirus.

11. The composition of claim 10 , wherein said first and second flaviviruses are, independently, selected from the group consisting of Yellow Fever, Japanese encephalitis, dengue-1, dengue-2, dengue-3, dengue-4, Murray Valley encephalitis, St. Louis encephalitis, West Nile, Kunjin, Rocio encephalitis, Ilheus, Central European encephalitis, Siberian encephalitis, Russian Spring-Summer encephalitis, Kyasanur Forest Disease, Alkhurma, Omsk Hemorrhagic fever, Louping ill, Powassan, Negishi, Absettarov, Hansalova, Apoi, and Hypr viruses.

12. The composition of claim 10 , wherein said second flavivirus is a Japanese encephalitis virus, a West Nile virus, or a dengue virus, and said first flavivirus is a yellow fever virus.

13. The composition of claim 1 , wherein the pH of said composition is 7.9-8.1 prior to freeze-drying.

14. The composition of claim 1 , wherein said lactose is present at a concentration of about 2-10% and said mannitol is present at a concentration of about 2-10% prior to freeze-drying.

15. The composition of claim 14 , wherein said lactose is present at a concentration of about 4% and said mannitol is present at a concentration of 5% prior to lyophilization.

16. The composition of claim 1 , wherein said composition does not comprise alanine.

17. A liquid composition comprising a live, attenuated flavivirus , one or more stabilizers, one or more buffer components, lactose, and mannitol, wherein said mannitol is in amorphous form upon freeze-drying of said composition, and said live, attenuated flavivirus is a chimeric flavivirus that comprises a first flavivirus in which one or more structural proteins have been replaced with corresponding structural proteins of a second, different flavivirus.

18. The composition of claim 17 , wherein the membrane and envelope proteins of said first flavivirus have been replaced with membrane and envelope proteins of said second, different flavivirus.

19. The composition of claim 18 , wherein said first and second flaviviruses are, independently, selected from the group consisting of Yellow Fever, Japanese encephalitis, dengue-1, dengue-2, dengue-3, dengue-4, Murray Valley encephalitis, St. Louis encephalitis, West Nile, Kunjin, Rocio encephalitis, Ilheus, Central European encephalitis, Siberian encephalitis, Russian Spring-Summer encephalitis, Kyasanur Forest Disease, Alkhurma, Omsk Hemorrhagic fever, Louping ill, Powassan, Negishi, Absettarov, Hansalova, Apoi, and Hypr viruses.

20. The composition of claim 18 , wherein said second flavivirus is a Japanese encephalitis virus, a West Nile virus, or a dengue virus, and said first flavivirus is a yellow fever virus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2015
From: WOISZWILLO, JAMES E.
To: ACAMBIS INC.
Reel/Frame 036276/0722 →
CHANGE OF NAME Recorded Aug 7, 2015
From: ACAMBIS INC.
To: SANOFI PASTEUR BIOLOGICS CO.
Reel/Frame 036307/0761 →
CHANGE OF NAME Recorded Aug 7, 2015
From: SANOFI PASTEUR BIOLOGICS CO.
To: SANOFI PASTEUR BIOLOGICS, LLC
Reel/Frame 036314/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2015
From: VELLOM, DANIEL C.; DEGEORGE, PAUL; CIARAMETARO, PETER
To: SANOFI PASTEUR BIOLOGICS, LLC
Reel/Frame 036251/0687 →
Continuity (2)
Provisional Application 60857424 · Nov 7, 2006
Related Publication 20100247573A1 · Sep 30, 2010